Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy

Overview of attention for article published in Drug Design, Development and Therapy, January 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#38 of 2,273)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 9 news outlets

patent: 1 patent

Citations

dimensions_citation: 31 Dimensions

Readers on

mendeley: 38 Mendeley

Summary News Patents Dimensions citations

So far, Altmetric has seen 9 news stories from 9 outlets.

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

PharmiWeb, 30 Jan 2019

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small…

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Business Journals, 30 Jan 2019

Can Fite’s drugs robustly inhibit the release of inflammatory mediators that induce Cytokine Release Syndrome (CRS), a…

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Biospace, 30 Jan 2019

Jan. 30, 2019 12:00 UTC Can Fite’s drugs robustly inhibit the release of inflammatory mediators that induce Cytokine Release…

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Wall Street Online Denmark, 30 Jan 2019

. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that…

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal - Press Release

Digital Journal, 30 Jan 2019

PETACH TIKVA, Israel--(Business Wire)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company…

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Morning Star, 30 Jan 2019

Can Fite’s drugs robustly inhibit the release of inflammatory mediators that induce Cytokine Release Syndrome (CRS), a…

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

NASDAQ, 30 Jan 2019

@media screen and (max-device-width: 480px){body{ font-size:30pt !important;}}.bwalignc {text-align: center}.bwuline {text-decora…

CanFites Drugs Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Bioportfolio, 30 Jan 2019

Can Fite’s drugs robustly inhibit the release of inflammatory mediators that induce Cytokine Release Syndrome (CRS), a…

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Business Wire, 30 Jan 2019

Can Fite’s drugs robustly inhibit the release of inflammatory mediators that induce Cytokine Release Syndrome (CRS), a…

Dove Medical Press

Article Metrics

Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy

About this Attention Score

Mentioned by

Citations

Readers on

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

PharmiWeb, 30 Jan 2019

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Business Journals, 30 Jan 2019

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Biospace, 30 Jan 2019

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Wall Street Online Denmark, 30 Jan 2019

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal - Press Release

Digital Journal, 30 Jan 2019

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Morning Star, 30 Jan 2019

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

NASDAQ, 30 Jan 2019

CanFites Drugs Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Bioportfolio, 30 Jan 2019

Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Business Wire, 30 Jan 2019